Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China

SU Zhicheng; LI Lu; YAO Qiang; ZHU Cairong; JIA Tao

doi:10.6039/j.issn.1001-0408.2024.22.12

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China

更新时间：2024-11-26

- Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China
- ZHONGGUO YAOFANG Vol. 35, Issue 22, Pages: 2773-2778(2024)
- 作者机构：
  
  1.四川大学华西公共卫生学院/四川大学华西第四医院流行病与卫生统计学系，成都　610041
  2.成都蓉生药业有限责任公司，成都　610093
  3.中国生物技术股份有限公司，北京　100011
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.22.12
  CLC： R956
- Published：30 November 2024，
  
  Received：27 May 2024，
  
  Revised：29 October 2024，
- 稿件说明：
移动端阅览
苏志铖,李璐,姚强等.卡介苗用于我国中高危非肌层浸润性膀胱癌患者TUR-BT术后灌注治疗的药物经济学评价 ^Δ[J].中国药房,2024,35(22):2773-2778.

SU Zhicheng,LI Lu,YAO Qiang,et al.Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China[J].ZHONGGUO YAOFANG,2024,35(22):2773-2778.
苏志铖,李璐,姚强等.卡介苗用于我国中高危非肌层浸润性膀胱癌患者TUR-BT术后灌注治疗的药物经济学评价 ^Δ[J].中国药房,2024,35(22):2773-2778. DOI： 10.6039/j.issn.1001-0408.2024.22.12.

SU Zhicheng,LI Lu,YAO Qiang,et al.Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China[J].ZHONGGUO YAOFANG,2024,35(22):2773-2778. DOI： 10.6039/j.issn.1001-0408.2024.22.12.

摘要

目的

对卡介苗（BCG）与表柔比星用于中高危非肌层浸润性膀胱癌（NMIBC）患者经尿道膀胱肿瘤切除术（TUR-BT）术后膀胱灌注治疗的经济性进行评价。

方法

从我国卫生体系角度出发，基于ChiCTR-IIR-16008357研究构建Markov队列模型。以质量调整生命年（QALYs）作为健康产出，意愿支付阈值设定为1倍2023年中国人均国内生产总值（89 358元/QALY）。采用成本-效用分析比较BCG方案相对表柔比星方案用于我国中高危NMIBC患者TUR-BT术后膀胱灌注治疗的增量成本-效果比（ICER），并进行敏感性分析。

结果

BCG方案相比于表柔比星方案的增量成本为34 309.51元，增量效用为0.800 QALYs，ICER为42 871.33元/QALY，低于意愿支付阈值。当意愿支付阈值为89 358元/QALY时，概率敏感性分析中BCG方案可被接受的概率为77.70%，高于表柔比星方案，且BCG方案的可接受性随意愿支付阈值的增加而增加。

结论

以1倍2023年我国人均GDP为意愿支付阈值时，相比表柔比星，BCG用于中高危NMIBC患者TUR-BT术后膀胱灌注治疗具有更好的经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of using Bacillus Calmette-Guérin （BCG） versus epirubicin for intravesical perfusion after transurethral resection of bladder tumor （TUR-BT） in patients with intermediate- to high-risk non-muscle-invasive bladder cancer （NMIBC）.

METHODS

From the perspective of China’s health system， a Markov cohort model was constructed based on the ChiCTR-IIR-16008357 study. Quality-adjusted life years （QALYs） were used as the health outcome measure， with the willingness-to-pay（WTP） threshold set at one time the per capita gross domestic product of China in 2023 （89 358 yuan/QALY）. A cost-utility analysis was used to compare the incremental cost-effectiveness ratio （ICER） of the BCG regimen relative to the epirubicin regimen for intravesical perfusion after TUR-BT in patients with intermediate- to high-risk NMIBC in China. In addition， sensitivity analysis was performed.

RESULTS

The incremental cost of the BCG regimen compared to the epirubicin regimen was 34 309.51 yuan， with an incremental utility of 0.800 QALYs， resulting in an ICER of 42 871.33 yuan/QALY， which is below the WTP threshold. When the WTP threshold was 89 358 yuan/QALY， the probability that the BCG regimen would be acceptable was 77.70% in the probabilistic sensitivity analysis， higher than that of the epirubicin regimen， and the acceptability of the BCG regimen increased with increasing in the WTP threshold.

CONCLUSIONS

When the WTP threshold was set at one time the per capita gross domestic product of China in 2023， compared to epirubicin， BCG used for intravesical perfusion after TUR-BT in patients with intermediate- to high-risk NMIBC demonstrated better cost-effectiveness.

关键词

卡介苗非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术膀胱灌注表柔比星药物经济学

Keywords

non-muscle-invasive bladder cancertransurethral resection of bladder tumorbladder perfusionepirubicinpharmacoeconomics

references

BRAY F，FERLAY J，SOERJOMATARAM I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68（6）：394-424.

MARIOTTO A B，ENEWOLD L，ZHAO J X，et al. Medical care costs associated with cancer survivorship in the United States[J]. Cancer Epidemiol Biomarkers Prev，2020，29（7）：1304-1312.

EBRAHIMI H，AMINI E，PISHGAR F，et al. Global，regional and national burden of bladder cancer，1990 to 2016：results from the GBD study 2016[J]. J Urol，2019，201（5）：893-901.

FLAIG T W，SPIESS P E，ABERN M，et al. NCCN guidelines® insights：bladder cancer，version 3.2024[J]. J Natl Compr Canc Netw，2024，22（4）：216-225.

黄健，张旭. 中国泌尿外科和男科疾病诊断治疗指南：2022版[M]. 北京：科学出版社，2022：39-129.

HUANG J，ZHANG X. Guidelines for the diagnosis and treatment of urological and andrological diseases in China：2022 edition[M]. Beijing：Science Press，2022：39-129.

BABJUK M，BURGER M，COMPÉRAT E M，et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer（TaT1 and carcinoma in situ）： 2019 update[J]. Eur Urol，2019，76（5）：639-657.

UCHIDA A，YONOU H，HAYASHI E，et al. Intravesical instillation of Bacille Calmette-Guérin for superficial bladder cancer：cost-effectiveness analysis[J]. Urology，2007，69（2）：275-279.

白志鹏，唐以众. TURBT联合表柔比星与羟喜树碱膀胱灌注对浅表性膀胱癌患者术后复发率及生活质量的影响[J]. 解放军医药杂志，2019，31（4）：40-43.

BAI Z P，TANG Y Z. Effects of TURBT combined with epirubicin and hydroxycamptothecin by intravesical instillation on postoperative recurrence rate and life quality of patients with superficial bladder cancer[J]. Med Pharm J Chin People’s Liberation Army，2019，31（4）：40-43.

吕嘉，王金万. 表柔比星膀胱灌注预防浅表性膀胱癌术后复发成本-效果分析[J]. 中国药业，2015，24（20）：48-49.

LYU J，WANG J W. Cost-effectiveness analysis of epirubicin bladder perfusion in preventing postoperative recurrence of superficial bladder cancer[J]. China Pharm，2015，24（20）：48-49.

陈学建，夏振和，陈茂章，等. 四种化疗药物膀胱灌注预防浅表性膀胱癌经尿道膀胱肿瘤切除术后复发的成本-效果研究[J]. 中国全科医学，2012，15（19）：2188-2190.

CHEN X J，XIA Z H，CHEN M Z，et al. Cost-effectiveness analyses of four drugs as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after TURBT[J]. Chin Gen Pract，2012，15（19）：2188-2190.

杨昕，丁全. 4种膀胱癌治疗方案的成本-效果分析[J]. 中国医院用药评价与分析，2001，1（2）：90-92.

YANG X，DING Q. Cost-effectiveness analysis of four therapeutic schemes for carcinoma of urinary bladder[J]. Eval Anal Drug Use Hosp China，2001，1（2）：90-92.

于浩，林天歆，李响，等. 卡介苗预防中、高危非肌层浸润性膀胱癌术后复发的有效性、安全性随机、对照、多中心临床试验中期报告[J]. 中华泌尿外科杂志，2019，40（7）：485-491.

YU H，LIN T X，LI X，et al. The efficacy and safety of BCG in the prevention of postoperative recurrence of intermediate and high-risk non-muscle invasive bladder cancer：a randomized，controlled，multi-center clinical trial：mid-term report[J]. Chin J Urol，2019，40（7）：485-491.

于浩，李锴文，胡海龙，等. 膀胱灌注国产卡介苗对比表柔比星预防中高危NMIBC复发的多中心、随机、对照研究2年疗效报告及复发风险因素分析[J]. 中华泌尿外科杂志，2020，41（10）：724-730.

YU H，LI K W，HU H L，et al. The efficacy of intravesical instillation of domestic BCG versus epirubicin in the prevention of recurrence of intermediate-risk or high-risk non-muscular invasive bladder cancer and predictive factors of BCG instillation：a randomized，controlled，multi-center clinical trial with 2 years’ follow-up[J]. Chin J Urol，2020，41（10）：724-730.

BRIGGS A，CLAXTON K，SCULPHER M. Decision modelling for health economic evaluation[M]. Oxford：Oxford University Press，2006：70-75.

赵子懿，吴玉伟，李明东，等. 卡介苗膀胱灌注用于中高危NMIBC患者治疗的有效性和安全性：一项真实世界研究[J]. 临床泌尿外科杂志，2023，38（12）：910-914，920.

ZHAO Z Y，WU Y W，LI M D，et al. Real-world study of efficacy and safety of BCG intravesical treatment for intermediate- and high-risk NMIBC[J]. J Clin Urol，2023，38（12）：910-914，920.

CHOU R，SELPH S，BUCKLEY D I，et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer：a systematic review and meta-analysis[J]. J Urol，2017，197（5）：1189-1199.

范钰，石明，熊子兵，等. 根治性膀胱全切术围手术期并发症风险因素分析[J]. 四川大学学报（医学版），2012，43（1）：99-103.

FAN Y，SHI M，XIONG Z B，et al. Critical analysis on risk factors of postoperative in-hospital complications in radical cystectomy of bladder cancer[J]. J Sichuan Univ Med Sci Ed，2012，43（1）：99-103.

何乾，张国辉. 保留膀胱的综合治疗与根治性膀胱切除术对肌层浸润性膀胱癌疗效的比较[J]. 癌症进展，2017，15（3）：334-337.

HE Q，ZHANG G H. Comparison of the efficacy of comprehensive bladder preservation surgery with radical cystectomy for muscle invasive bladder cancer[J]. Oncol Prog，2017，15（3）：334-337.

ZHENG W，LI X S，SONG G，et al. Comparison of laparoscopic and open cystectomy for bladder cancer：a single center of 110 cases report[J]. Transl Androl Urol，2012，1（1）：4-8.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版，2020：1-15.

LIU G E. Guidelines for pharmaceutical economics evalua-tion in China 2020[M]. Beijing：China Market Press，2020：1-15.

KULKARNI G S，ALIBHAI S M H，FINELLI A，et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guérin therapy for high-risk，high-grade（T1G3）bladder cancer[J]. Cancer，2009，115（23）：5450-5459.

国家卫生健康委员会.2021年我国卫生健康事业发展统计公报[EB/OL].[2024-09-27].https：//www.gov.cn/xinwen/2022-07/12/content_5700670.htmhttps://www.gov.cn/xinwen/2022-07/12/content_5700670.htm.

National Health Commission. Statistical bulletin on the development of health and health care in China in 2021[EB/OL].[2024-09-27].https：//www.gov.cn/xinwen/2022-07/12/content_5700670.htmhttps://www.gov.cn/xinwen/2022-07/12/content_5700670.htm.

靳英辉，曾宪涛.中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南：2018年标准版 [J]. 现代泌尿外科杂志，2019，24（7）：516-542.

JIN Y H，ZENG X T. Treatment and surveillance for non-muscle-invasive bladder cancer in China：an evidence-based clinical practice guideline：2018 simplified version [J]. J Mod Urol，2019，24（7）：516-542.

PASTA D J，TAYLOR J L，HENNING J M. Probabilistic sensitivity analysis incorporating the bootstrap：an exam-ple comparing treatments for the eradication of Helicobacter pylori[J]. Med Decis Making，1999，19（3）：353-363.

EDLIN R，MCCABE C，HULME C，et al. Cost effectiveness modelling for health technology assessment：a practical course[M]. Cham：Springer International Publishing，2015：105-118.

冯国双. 白话统计[M]. 北京：电子工业出版社，2018：92-96.

FENG G S. Vernacular statistics[M]. Beijing：Publishing House of Electronics Industry，2018：92-96.

REED J F. Better binomial confidence intervals[J]. J Mod App Stat Meth，2007，6（1）：153-161.

国家统计局.中华人民共和国2023年国民经济和社会发展统计公报[EB/OL].[2024-09-27]. https：//www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.htmhttps://www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.htm.

National Bureau of Statistics. Statistical bulletin on national economic and social development of the People’s Republic of China in 2023[EB/OL]. [2024-09-27]. https：//www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.htmhttps://www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.htm.

叶子平，马佳，刘抚瑶，等. 以1～3倍人均GDP作为药物经济学阈值的文献溯源及概念分析[J]. 中国卫生经济，2020，39（5）：72-75.

YE Z P，MA J，LIU F Y，et al. Literature tracing and conceptual analysis of 1-3 times GDP per capita as pharmacoeconomic threshold[J]. Chin Health Econ，2020，39（5）：72-75.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of sacituzumab govitecan versus single-agent chemotherapy in the treatment of HR+/HER2－ advanced metastatic breast cancer

Pharmacoeconomic evaluation of trastuzumab deruxtecan versus chemotherapy in the second-line treatment of advanced breast cancer with HER-2 low expression

Optimization of cost-utility analysis with equal value of life-year gained： a case study of RAS-mutant metastatic colorectal cancer

Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma

Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”

Related Author

HE Yinmei

LI Xiao

LIU Xiaoli

LI Longzhou

GAO Yan

YU Jianguo

LUAN Jiajie

WU Yilai

Related Institution

Dept. of Clinical Pharmacy， Yijishan Hospital of Wannan Medical College

Dept. of Pharmacy， the Second Affiliated Hospital of Wannan Medical College

Breast Center， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Pharmacology， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰